PortViewPortView
Lunai Bioworks logo

Lunai Bioworks (LNAI) Stock Analysis

NASDAQHealthcareBiotechnology

$0.24-6.50%
1-year price historyRange $0.24 – $12.00
52-week range$0.24
$0.20$13.28

Track LNAI in your portfolio for free · Portfolio tracker

What Lunai Bioworks does

Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."

Key metrics

Market cap
$1.07M
EPS (TTM)
$-61.29
Beta
0.35
Dividend yield
0.00%
Revenue / share
$0.01
50-day avg
$1.69
200-day avg
$2.98
52-week high
$13.28
52-week low
$0.20
CEO
David H. Weinstein

ETFs linked to LNAI

Broad-market and Healthcare sector ETFs an investor holding Lunai Bioworks is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how LNAI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze LNAI in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Lunai Bioworks?
Lunai Bioworks trades under the ticker LNAI on NASDAQ.
Which exchange is LNAI listed on?
LNAI is listed on NASDAQ.
What sector does Lunai Bioworks operate in?
Lunai Bioworks is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze LNAI in a portfolio?
PortView shows LNAI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.